Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
151.51
-3.86 (-2.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump
↗
December 09, 2025
The AI-powered genetic-testing company has been a strong performer. The CEO's recent move had more to do with accounting than conviction.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Option Care Health Bring Home Hefty Share Price Gains; Earns RS Rating Upgrade
↗
November 26, 2025
The upgraded 74 RS Rating shows that the Chicago area-based home health care firm tops more than 70% of stocks for price performance.
Via
Investor's Business Daily
GeneDx Holdings Corp (NASDAQ:WGS) Presents a Strong Case for Growth Momentum and Technical Breakout
↗
November 20, 2025
GeneDx (WGS) shows explosive earnings growth of 1,125% and strong technicals, presenting a high-growth momentum and breakout opportunity.
Via
Chartmill
Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake?
↗
November 19, 2025
The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.
Via
The Motley Fool
Earnings Scheduled For October 28, 2025
↗
October 28, 2025
Via
Benzinga
GeneDx Hldgs's Earnings: A Preview
↗
October 27, 2025
Via
Benzinga
6 Healthcare Stocks With Strong Upward Momentum
↗
November 18, 2025
Via
Benzinga
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
↗
November 14, 2025
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
Via
The Motley Fool
Topics
Artificial Intelligence
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
↗
November 12, 2025
BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?
Via
The Motley Fool
Topics
Artificial Intelligence
Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing
↗
November 11, 2025
Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
November 06, 2025
From
GeneDx
Via
Business Wire
GeneDx Holdings Corp (NASDAQ:WGS) Emerges as a Premier Growth and Momentum Stock
↗
November 05, 2025
GeneDx (WGS) stock aligns with growth & momentum strategies, showing a powerful uptrend backed by explosive earnings growth and strong technical health.
Via
Chartmill
GeneDx to Participate in Upcoming Investor Conferences
November 04, 2025
From
GeneDx
Via
Business Wire
What Does the Market Think About GeneDx Holdings Corp?
↗
October 31, 2025
Via
Benzinga
GeneDx (WGS) Q3 2025 Earnings Call Transcript
↗
October 28, 2025
GeneDx (WGS) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
GeneDx Holdings Corp (NASDAQ:WGS) Q3 2025 Earnings Beat Estimates and Drive Stock Higher
↗
October 28, 2025
GeneDx Q3 2025 earnings crush estimates with 52% revenue growth. Strong exome/genome test demand and raised 2025 guidance fuel investor optimism.
Via
Chartmill
Topics
Earnings
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
October 28, 2025
From
GeneDx
Via
Business Wire
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
October 24, 2025
From
Halper Sadeh LLC
Via
Business Wire
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
October 22, 2025
From
GeneDx
Via
Business Wire
4 Analysts Assess GeneDx Holdings: What You Need To Know
↗
October 20, 2025
Via
Benzinga
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
October 20, 2025
From
GeneDx
Via
Business Wire
This WillScot Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
October 20, 2025
Via
Benzinga
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
October 14, 2025
From
GeneDx
Via
Business Wire
GeneDx Holdings Corp (NASDAQ:WGS) Presents a High-Growth Momentum and Technical Breakout Case
↗
October 14, 2025
GeneDx stock shows strong growth momentum with 600% EPS growth and a bullish technical setup, signaling a potential breakout for investors.
Via
Chartmill
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
October 13, 2025
From
GeneDx
Via
Business Wire
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
October 09, 2025
From
GeneDx
Via
Business Wire
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
October 08, 2025
From
GeneDx
Via
Business Wire
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
October 07, 2025
From
GeneDx
Via
Business Wire
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
October 01, 2025
From
GeneDx
Via
Business Wire
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
September 30, 2025
From
GeneDx
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.